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Parkinsonism refers to a set of conditions featuring motor symptoms such as slowness, 
tremor, and rigidity that are most commonly observed in older patients. Forms of Parkinsonism, 
including Parkinson’s disease (PD) and drug-induced Parkinsonism (DIP), can be difficult to 
distinguish clinically and are associated with dysfunction in a subcortical brain region known as 
the basal ganglia, a group of structures which include the striatum. The basal ganglia receive 
dopaminergic projections from the substantia nigra pars compacta (SNc), and interfacing with 
the extrapyramidal system, these brain regions are critical in the regulation of involuntary and 
voluntary motor movements. Input from premotor areas and the cerebral cortex relay signals to 
the caudate and putamen forming the indirect and direct pathways. Both of which have 
competing, yet balanced, effects on movement. Reductions in either dopamine signaling or 
numbers of projecting neurons in these pathways leads to Parkinsonism. DIP can be initiated by 
dopamine receptor blocking agents, including first- (FGA) and second-generation (SGA) 
antipsychotic drugs, which block D2 dopaminergic receptors. FGAs and SGAs primarily differ in 
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D2 receptor affinity, with FGAs generally being higher. FGAs are more likely to cause DIP than 
SGAs, but despite the difference in receptor affinities, they are both capable of inducing motor 
deficits at varying concentrations. Unlike in PD, motor deficits in DIP may be alleviated upon 
withdrawal of the offending drug, but in some cases, patients continue to experience 
Parkinsonism symptoms for years. It is not known whether these more permanent forms of DIP 
may result from damage in the basal ganglia caused by FGAs and SGAs. Based on a review of 
the literature, evidence that prolonged exposure to, or high concentrations of these drugs, 
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PD  Parkinson’s disease 
DIP  Drug-induced parkinsonism  
SNc  Substantia nigra pars compacta 
FGA  First generation antipsychotics 
SGA  Second generation antipsychotics  
MSN  Medium spiny neurons 
GPi  Globus pallidus internus 
SNr  Substantia nigra pars reticulata  
GPe  Globus pallidus externus  
STN  Subthalamic nucleus  
CSF  Cerebrospinal fluid 




A motor disability composed of tremor, bradykinesia, rigidity, and postural instability 
was first described in 1817 by James Parkinson and was called the “Shaking Palsy” and is the 
disease we call Parkinson’s today, but a range of symptoms are observed, and it can be 
accompanied by depression, emotional instability, and difficulties in cognition [1, 2]. The name 
Parkinson’s Disease, or PD, was later suggested by Jean-Martin Charcot to better encompass 
these differences among affected individuals. PD can also be described by the broader term 
“parkinsonism,” which refers to any disorder that causes motor symptoms of PD [1]. The 
neurodegeneration of dopaminergic neurons creates a permanence to the motor effects. PD is 
usually observed in elderly individuals and progresses with age, and rarely appears in those 
younger than 60 years old [3].  
Beginning symptoms of PD are often difficult to detect. Later, symptoms progress and 
become more apparent, possibly a result of protein deposits called Lewy bodies that build up and 
disrupt the production of important neurotransmitters [4]. Other possible contributions to 
progression of the disorder include abnormalities in the motor loop of the basal ganglia [5]. 
Specifically, defects in the dopaminergic neurons that project from the substantia nigra and 
synapse onto striatal cells, where they normally release dopamine, are thought to play an 
important role [6]. These defects may include excessive cell death, mitochondrial dysfunction, 
abnormal signaling from astrocytes, and misfolding of the protein α-synuclein. 
Drug-induced parkinsonism (DIP) is a form of the disorder caused by exposure to drugs, 
including primarily antipsychotic drugs, which block dopamine signaling in the basal ganglia. 
Since, both PD and DIP produce the same motor defects, DIP is often misdiagnosed as PD. 
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Patients with PD experience symptoms and neuron degeneration with increasing age. 
Meanwhile, patients with DIP may encounter symptoms at any age, but cases are most prevalent 
in old age [7]. The prevalence and degree of motor symptoms in DIP depend on which 
antipsychotics and doses were administered, and for how long. Furthermore, nuclear imaging 
techniques have shown distinct differences in the basal ganglia of affected patients, with PD 
patients having asymmetrical defects across the two hemispheres, whereas in DIP they are 




1. NEUROANATOMICAL BASIS FOR THERAPEUTIC AND SIDE 
EFFECTS ASSOCIATED WITH ANTIPSYCHOTIC DRUG TREATMENT 
Antipsychotic drug treatment is most commonly given for illnesses with psychotic 
features, including schizophrenia. These drugs are known to have many adverse side effects due 
to their effect on several different neurotransmitter systems, including their profound antagonism 
of dopamine receptors. Dopamine receptors, found throughout the brain, are guanine nucleotide 
binding protein (G-protein) coupled receptors that are bound to the membrane. They are located 
both presynaptically and postsynaptically, and there are five different dopamine receptors:  D1, 
D2, D3, D4, and D5, the functions of which are shown in Table 1 [9]. Dopamine D1 and D5 
receptor subtypes are collectively called D1-type, while D2, D3, and D4 subtypes are called D2-
type, and they initiate, or inhibit, the cyclic AMP (cAMP) second messenger pathway, 
respectively, to produce a cellular response [10]. Both D1- and D2-types are located 
postsynaptically on striatal GABAergic neurons, known as medium spiny neurons (MSNs), 
while D2-type are additionally found on cholinergic interneurons in the basal ganglia. D1-
expressing MSNs make up the direct pathway, the stimulation of which activates inhibitory 
striatal efferents directly onto the globus pallidus internus (GPi) and substantia nigra pars 
reticulata (SNr). D2-expressing MSNs make up the indirect pathway of the brain, another set of 
inhibitory striatal neurons that indirectly project to the SNr by way of the globus pallidus 
externus (GPe) and subthalamic nucleus (STN). Both pathways receive initiating signals from 
the cortex and send information to the thalamus, where they have opposing net effects [11]. 
Dopamine production and release levels are additionally influenced by D2 receptors located 
presynaptically on dopaminergic neuron terminals, and dopamine is cleared from the synapse by 
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the dopamine transporter, or DAT, which is also located presynaptically. Degeneration of the 
neurons that release dopamine directly affects dopaminergic receptors, making them unable to 
project signals that are responsible for coordinated movement output [12]. 
Table 1: The Five Dopamine Receptor Sub-Types and Functions [9]. 
Dopamine Receptor Types Dopamine Receptor Function 
D1  Locomotion, attention, sleep, regulation of renal function, impulse control, learning, and memory 
D2 Locomotion, attention, sleep, reproductive behavior, learning, and memory 
D3 Locomotion, attention, sleep, cognition, impulse control, and regulation of food intake 
D4 Cognition, attention, sleep, impulse control, and reproductive behavior  
D5 Cognition, attention, decision making, renin secretion, and motor learning  
 
While it is somewhat controversial, it is thought that antipsychotics have their primary 
therapeutic effect, correcting the positive symptoms (e.g., hallucinations) in schizophrenia, for 
example, by blocking D2 receptors in the limbic system. However, these drugs have affinity for 
all D2 receptors throughout the brain [14], and their blockade in the basal ganglia and resulting 
negative impact on the extrapyramidal system cause problems relating to locomotion. The 
extrapyramidal system is a network of brain regions that includes the basal ganglia, 
cerebellum, premotor, and supplementary motor areas, which are responsible for voluntary and 
involuntary movement.  
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Antipsychotic drugs are split into two different classes based on when they were 
developed. First-generation antipsychotics (FGAs), developed earlier, have higher affinities for 
the dopamine D2 receptor and are two times more likely to cause DIP than second-generation 
antipsychotics (SGAs), as shown in Table 2. Chlorpromazine, an example of an FGA, induces 
parkinsonism in 40% of users and aripiprazole, an SGA, induces parkinsonism in over 2% of 
users [15, 13]. In addition, FGAs are more likely to cause persisting DIP, lasting months to years 
after withdrawal of the drug. DIP percentages today are much better than they were at the time of 
FGA production because of the development of SGAs, decreasing the likelihood of parkinsonism 
[16]. SGAs quetiapine and clozapine have been shown least likely among the antipsychotics to 
produce DIP in patients [17]. However, it is important to note that both SGAs and FGAs are 













Table 2: FGA and SGA Parkinsonism Adverse Effect Frequency [13]. 
Antipsychotic Class Compound Adverse Effect Frequency 
FGA Chlorpromazine Moderately frequent 
FGA Fluphenazine Frequent  
FGA Haloperidol Frequent 
FGA Trifluoperazine Frequent 
SGA Amisulpride Moderately frequent 
SGA Aripiprazole Infrequent  
SGA Clozapine Infrequent 
SGA Olanzapine Infrequent 
SGA Quetiapine Infrequent 




2. POSSIBLE MECHANISMS UNDERLYING DIP 
DIP is estimated to appear days to weeks after treatment with antipsychotics has begun, 
but in some cases, DIP appears years after the drug is discontinued. The average DIP patient 
taking antipsychotic drugs should be able to withdraw from the FGA or SGA and recover from 
all extrapyramidal motor symptoms within days to years. However, a number of factors can 
interfere with this process. Some patients with severe symptoms from psychotic disorders may 
be unable to discontinue the offending drug. If possible, patients taking FGAs in this situation 
may be changed to SGAs to attempt the reduction of DIP and continue management of psychotic 
symptoms. Long-term exposure or high concentrations of SGAs are more likely to promote DIP 
[7], thus patients that require the assistance of FGAs or SGAs in higher concentrations should be 
routinely monitored.  
The basal ganglia contain high levels of catecholamines and iron, which in radical form 
can induce oxidative stress. Previously, it was found that prolonged administration of 
antipsychotics in patients experiencing extrapyramidal side effects is associated with an increase 
in protein carbonyl oxidation products, an increase in markers of oxidative stress in the 
cerebrospinal fluid (CSF), and their symptoms are negatively correlated with superoxide 
dismutase levels. Reductions in superoxide dismutase, an enzyme that mediates partitioning 
(dismutation) of the superoxide radical into oxygen and hydrogen peroxide, allow more 
oxidative stress and neuronal damage to occur and may relate, specifically, to the degeneration of 
striatal GABAergic neurons. Decreased superoxide dismutase is reported in schizophrenia 
patients that are most prone to DIP [19].  
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The number of glutamatergic corticostriatal synapses increases as a result of 
antipsychotic treatment, specifically haloperidol. D2 receptor blockade on corticostriatal 
glutamate neurons increases the release of the neurotransmitter glutamate by 50% [20]. 
Clozapine and sulpiride, SGAs, were found unable to increase striatal glutamate indicating that 
they are not likely to induce extrapyramidal side effects [21]. The increased number of 
glutamatergic corticostriatal synapses, which decrease upon withdrawal, may be related to the 
developed tolerance that can be observed for extrapyramidal symptoms [20]. Haloperidol was 
found to increase glutamate release in the corpus striatum, and the authors concluded that it and 
perhaps other FGAs are more likely than SGAs to impact this region strongly [22].  
Another study found evidence of haloperidol toxicity by analyzing elevated plasma levels 
of membrane lipid peroxidation, which is associated with oxidative stress that causes 
neurodegeneration. FGA, and specifically haloperidol, -treated patients showed an increase in 
lipid peroxidation unlike those treated with the SGA olanzapine. Patients taking haloperidol 
expressed significantly reduced levels of antioxidants, including ascorbate and alpha tocopherol. 
As both are required in the process of interrupting free radical propagation, these changes may 
upset the balance of redox reactions [23, 24].  
Previous research has attempted to use this information to investigate prevention of the 
development of DIP. Vitamin E is a known antioxidant, able to break down oxidative substances 
in the nigrostriatal pathway [24, 25]. One study found that combining vitamin E with 
antipsychotic drugs, haloperidol, perphenazine, and chlorpromazine, in patients with 
schizophrenia resulted in a trend towards increased prevention of DIP without affecting the 
antipsychotic’s ability to treat symptoms. However, there was no evidence of vitamin E 
lessening the severity of akathisia, another antipsychotic-induced movement disorder. Despite 
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limitations on the number of subjects in the study, vitamin E should be further investigated for its 




3. DOPAMINE TRANSPORTER IMAGING COMPARATIVE 
EFFECTS OF ANTIPSYCHOTIC DRUG USE 
As mentioned, the DAT, or dopamine transporter, is located on the presynaptic side of 
dopaminergic synapses and functions to reuptake extracellular dopamine back into the 
presynaptic terminal. Movement of dopamine back into the presynaptic neuron ensures that 
dopamine signaling remains brief and meaningful in the conveyance of information and 
maintains a normal level of synaptic influence over motor output. The DAT can be visualized 
using non-invasive imaging technologies, such as single photon emission computed tomography 
(SPECT), as well as positron emission tomography (PET), to determine its location and 
concentration in the brain [27]. Both techniques involve the usage of radioligands that are fused 
to drugs having high affinity for and that reversibly bind to the DAT, making them safe for use 
clinically. SPECT scans utilize N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-123I-
iodophenyl)nortropane (123I-FP-CIT) and 123I-2β-carbomethoxy-3β-(4-iodophenyl)tropane (123I-
β-CIT). 123I-FP-CIT has more affinity to DAT and faster kinetic properties than 123I-β-CIT [28]. 
PET scans utilize [18F]-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-
phenyl)nortropane (18F-FE-PE2I) and 11C-N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-
methylphenyl)nortropane (11C-PE2I). 18F-FE-PE2I has a greater affinity for DAT than 11C-PE2I 
[29]. All PET and SPECT radioligands are primarily used for research purposes except for 123I-
FP-CIT, which is used for medical practices [30].   
Guidelines for interpreting SPECT suggest that DAT-binding can indicate presynaptic 
dopamine terminal presence and may be used to distinguish in subclinical PD from DIP [31]. 
Using this method, another study addressed the confusing fact that incompletely recovered DIP 
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patients still experience the physical symptoms of DIP while expressing what appears to be 
normal DAT density. The authors compared DIP patients that were partially recovered and 
completely recovered using 18F-FP-CIT PET scan and used a semi-quantitative analysis that 
allowed relative density comparisons. Their findings showed that partially recovered patients 
indeed have slightly decreased DAT binding in the ventral striatum and putamen compared to 
fully recovered, but this difference may not be appreciated or recognized in basic imaging 
findings. The authors conclude that continued parkinsonism in partially recovered patients is 





In conclusion, the findings reported in the literature support that antipsychotics are 
capable of producing permanent forms of PD. Evidence of impaired antioxidant defense in 
patients treated with antipsychotics suggests neurotoxicity is caused by FGAs, especially 
haloperidol. Given that DIP is more likely to appear in the elderly, damage induced by 
antipsychotics or other drugs may interact with naturally occurring age-related reductions in 
dopaminergic neuron function. These findings suggest that patients should receive DAT-binding 
imaging using SPECT, or similar techniques, upon initial appearance of any motor dysfunction 
characteristic of DIP and PD, which may help to determine proper clinical diagnosis. In addition, 
screenings should be done routinely for patients taking antipsychotics to document signs of 
parkinsonism and determine change over time within-patient. Lastly, administration of vitamin E 
should be investigated further as an option that can reduce the severity or likelihood of DIP in 
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